Table 3.

Estrogen use (either from estrogen or estrogen + progesterone combination products) among women of the MEDALZ study according to age at the beginning of the follow-up period (date of AD diagnosis)

	35–54.9 years		55–64.9 years		65–105 years
	AD n = 162	No AD n = 162	AD n = 961	No AD n = 961	AD n = 44,993	No AD n = 44,993
Estrogen use, n (%)
No use in 1995–2012	125 (77.2)	109 (67.3)	579 (60.3)	539 (56.1)	39,060 (86.8)	39,188 (87.1)
Discontinued before index date	14 (8.6)	12 (7.4)	205 (21.3)	188 (19.6)	4707 (10.5)	4103 (9.1)
Use before and after index date (prevalent user)	16 (9.9)	28 (17.3)	166 (17.3)	220 (22.9)	1085 (2.4)	1567 (3.5)
Use after index date only (incident user)	7 (4.3)	13 (8.0)	11 (1.1)	14 (1.5)	141 (0.3)	135 (0.3)
Use of combination products, n (%)
Discontinued before index date	0	0	0	0	0	0
Use before and after index date (prevalent user)	6 (4.5)	7 (6.0)	70 (10.8)	90 (14.3)	1064 (2.7)	1019 (2.5)
Use after index date only (incident user)	2 (1.5)	1 (0.9)	2 (0.3)	1 (0.2)	2 (< 0.01)	4 (0.1)
Mean (95% CI) time lag between index date and last purchase after index date (years)	1.91 (0.87–2.96)	3.32 (2.30–4.36)	1.27 (0.57–1.97)	2.63 (1.66–3.59)	2.28 (1.98–2.58)	2.67 (2.36–2.98)
Median (95% CI) time to discontinuation after index date (years)	3.34 (3.28–4.21)	3.97 (3.38–4.55)	2.49 (2.21–2.77)	3.17 (2.91–3.42)	1.96 (1.85–2.05)	3.01 (2.91–3.11)
Reason for ending the estrogen use, n (% of incident/prevalent users)
Use period ended	16 (69.7)	0	170 (96.1)	232 (99.1)	833 (68.0)	895 (52.6)
Death	3 (13.0)	0	4 (2.3)	2 (0.9)	46 (3.8)	44 (2.6)
90+ days hospitalization/institutionalization	3 (13.0)	41 (100)	3 (1.7)	0	93 (7.6)	30 (1.8)
End of data linkage	1 (4.3)	0	0	0	254 (20.7)	733 (43.1)

AD Alzheimer’s disease, CI confidence interval, MEDALZ Medication and Alzheimer’s Disease